Ford Motor Company (F) announced on Wednesday the addition of two new board members.
The automaker named James P. Hackett and John C. Lechleiter as the newest members of the company’s board of directors. Hackett’s new role will begin immediately, while Lechlieter will officially join on October 1, 2013.
Hackett is currently the CEO of Steelcase, Inc–a furniture maker–and also serves on the board of Fifth Third Bancorp, the National Center for Arts and Technology, and the��Gerald R. Ford School of Public Policy and Life Sciences Institute at University of Michigan. Lechlieter is the President and CEO of Eli Lilly and Company, one of the largest pharmaceutical firms in the world, and also serves on the board of Nike, Inc, United Way�Worldwide, Xavier University, the Central Indiana Corporate Partnership and the Life Sciences Foundation.
Top Clean Energy Companies To Buy For 2015: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 34.74 percent to $35.15 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Hot Life Sciences Stocks To Buy Right Now: Redrow PLC (RDW)
Redrow PLC is a United Kingdom-based company engaged in residential development, which includes mixed use development. The Company�� operations are primarily focused on house building. Its completed projects include Signature, In the City/Regeneration and Debut. The Company's land holdings consist of both a current and forward land bank. As of June 30, 2010, the current land bank consisted of 11,600 plots owned with planning and 1,570 contracted plots, and its forward lank bank stood at around 22,000 plots. Its subsidiaries include Redrow Homes (Scotland) Ltd, Redrow Homes (Yorkshire) Ltd, Redrow Homes (Lancashire) Ltd, Redrow plc & Redrow Homes (NW) Ltd, Redrow Homes (Midlands) Ltd, Redrow Homes (South Midlands) Ltd, Redrow Homes (South West) Ltd, Redrow Homes (South Wales) Ltd and Redrow Homes (Eastern) Ltd. Advisors' Opinion:- [By Namitha Jagadeesh]
Redrow Plc (RDW) rallied 3.2 percent to 245.6 pence as Deutsche Bank AG increased its 12-month share-price estimate and profit forecasts for 2013 and 2014. The U.K. builder yesterday jumped the most in five months after saying pretax profit for the year ended June will beat analysts��estimates.
Hot Life Sciences Stocks To Buy Right Now: KB Home (KBH)
KB Home is a homebuilding company. The Company constructs and sells homes through its operating divisions under the name KB Home. The Company operates in nine states and 32 markets, including California, Arizona, Nevada, Colorado, Texas, Florida, Maryland, North Carolina and Virginia. The Company organizes its homebuilding operations into four segments: West Coast, Southwest, Central and Southeast. In July 2012, it acquired land within the Elworthy Ranch property in the town of Danville. In September 2012, it acquired Mason Ranch, which is a 330-acre land asset in Cedar Park/Leander West, submarkets in metropolitan Austin. In December 2012, the Company acquired 65 lots in Fuquay-Varina, N.C.
Homebuilding
The Company�� homebuilding operations offers a variety of homes designed primarily for first-time, move-up and active adult homebuyers, including attached and detached single-family homes, townhomes and condominiums. It offers homes in development communities, at urban in-fill locations and as part of mixed-use projects. During the fiscal year ended, November 30, 2011 (fiscal 2011), the Company, through its homebuilding segment, delivered 5,812 homes. During fiscal 2011, homebuilding operations accounted for 99.2% of the total revenues.
Financial Services
The financial services segment provides title and insurance services to its homebuyers. This segment also provided mortgage banking services to the Company�� homebuyers indirectly through KBA Mortgage, LLC (KBA Mortgage), a former unconsolidated joint venture of a subsidiary of ours and a subsidiary of Bank of America, N.A., from the venture�� formation until June 30, 2011, when it ceased offering mortgage banking services. Effective June 27, 2011, it entered into a marketing services agreement with MetLife Home Loans, a division of MetLife Bank, N.A. Under the agreement, MetLife Home Loans��personnel, located on site at several of its new home communities, can offer financing options and re! sidential consumer mortgage loan products to its homebuyers, and originate residential consumer mortgage loans for homebuyers who elect to use MetLife Home Loans. The Company�� homebuyers may also elect to use other providers of mortgage banking services. Its financial services operations accounted for 0.8% of the Company�� total revenues in fiscal 2011.
Advisors' Opinion:- [By Michael Lewis]
3. Bargain hunting
In keeping with the theme from the last point, there are plenty of options for investors who may feel as if they are late to the game. Single-family developers such as Lennar (NYSE: LEN ) and KB Homes (NYSE: KBH ) have seen tremendous market gains in the past two years. The former's stock has appreciated nearly 120%, while the latter is up 90%. It is not to say that single-family developers will not perform in the coming months and years, but there may be greater opportunity with the lagging multi-family plays. - [By DailyFinance Staff]
The looming Fed taper has been the talk of Wall Street for months, but it still came as a surprise to investors when it actually happened. Stocks rallied Wednesday following the Fed's decision to cut its $85 billion a month purchase of bonds by $10 billion, beginning in January. Outgoing Fed Chairman Ben Bernanke said the economy continues to "make progress." The Dow Jones industrial average (^DJI) soared 292 points on the news, its third biggest one-day gain this year. The Dow also hit a closing high, as did the Standard & Poor's 500 index (^GPSC), which gained 29 points. And the Nasdaq composite (^IXIC) rose 46 points. Consider it Bernanke's final present to the market before he retires from his position atop the Fed. Among the big blue chip winners, 3M (MMM) rose 3 percent, while Exxon Mobil (XOM), Chevron (CVX) and Goldman Sachs (GS) all rose 2 percent. But Microsoft (MSFT) was flat, reflecting across the board weakness in tech stocks. Many of the biggest players on the Nasdaq lost ground despite the overall market rally. Apple (AAPL) and Twitter (TWTR) ended lower and Tesla (TSLA) lost nearly 3 percent. Part of the reason for the tech weakness was an earnings miss and a weak forecast from Jabil Circuits (JBL), a key maker of electronics. Its shares plunged 20 percent. But homebuilders were strong following a report showing that housing starts last month rose to highest level in nearly six years. Lennar (LEN), which also posted strong earnings, jumped 6 percent. William Lyon Homes rose 4 percent, KB Homes (KBH) and Toll Brothers (TOL) each rose 3.5 percent. Ford (F) shares skidded more than 6 percent after lowering its profit forecast for next year. The company also warned that it may not meet its target for 2015 and 2016. In part, Ford blames the high expenses tied its planned launch of a record number of new vehicles next year. Finally, the movie theater chain AMC Entertainment (AMC) rose 5 percent from its $18 a share IPO price. This is exp
- [By Ben Levisohn]
Lennar (LEN) reported earnings today that were solid enough to boost the entire sector, despite mixed numbers from fellow homebuilder KB Home (KBH). The Wall Street Journal has the details:
- [By WWW.DAILYFINANCE.COM]
Patrick T. Fallon/Bloomberg via Getty Images Toll Brothers' quarterly profit more than doubled as a recovering housing market allowed the largest U.S. luxury homebuilder to sell more homes at higher prices, sending its shares up 4 percent. The company, which sells homes that can cost more than $2 million, has been able to perform better during the past few quarters than most large U.S. homebuilders as its buyers were less affected by a recent rise in mortgage rates. Toll's average selling price rose about 22 percent to $706,000 in the second quarter ended April 30 -- a period well into the spring selling season, which is to homebuilders what the holiday shopping season is to retailers. Toll (TOL), which mainly builds single-family houses, handed over 1,218 homes in the quarter, up 36 percent from a year earlier. While the company's sales remain strong, it decided last year to build and rent apartments to cater to the demand for rentals as higher interest rates and slow income growth pushes home ownership out of reach for many Americans. Permits to build multifamily housing such as apartment blocks rose 19.5 percent in the United States last month, compared with a 0.3 percent rise in permits for single-family homes. Toll Brothers said Wednesday it had about 1,500 rental units under construction and that it controlled sites for another 3,800. Lennar (LEN), the second-largest U.S. homebuilder, is the only other builder that is offering apartment rental units. 'Impressive Results' Toll's net income soared to $65.2 million, or 35 cents a share, in the second quarter from $24.7 million, or 14 cents a share, a year earlier. Revenue jumped 67 percent to $860.4 million. Orders stayed almost flat at 1,749 homes, compared with a 6 percent fall in the first quarter. "We are in a leveling period in the early stages of the housing recovery with significant pent-up demand building," Chief Executive Officer Douglas Yearley said in a statement. UBS analyst Davi
Hot Life Sciences Stocks To Buy Right Now: ABIOMED Inc.(ABMD)
Abiomed, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company?s products are designed to enable the heart to rest, heal, and recover by enhancing blood flow and/or performing the pumping function of the heart. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. Its products are used in the cardiac catheterization lab by interventional cardiologists and/or in the heart surgery suite by heart surgeons. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. Abiomed, Inc. was founded in 1981 and is based in Danvers, Massachusetts.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on ABIOMED (Nasdaq: ABMD ) , whose recent revenue and earnings are plotted below. - [By John Udovich]
Small cap heart stocks Sunshine Heart Inc (NASDAQ: SSH), Abiomed, Inc (NASDAQ: ABMD) and AtriCure Inc (NASDAQ: ATRC) each find different ways go to the heart of the problem for cardiac�patients and have all been good performers for investors this year. After all and according to statistics collected by the CDC, heart disease is the leading cause of death for both men and women as about 600,000 people die of heart disease in the United States every year���accounting�for 1 in every 4 deaths. Moreover, roughly 715,000 Americans have a heart attack every year and�ff these, 525,000 are a first heart attack and 190,000 happen to people who have already had one. In other words, there is a big market for the following small cap heart stocks to address:
- [By Todd Campbell]
So far I've outlined the reasons for the robust returns last year at diabetes device maker Dexcom and cardiovascular device play Cardiovascular Systems (NASDAQ: CSII ) . That brings us to No. 3 in my series,�Abiomed (NASDAQ: ABMD ) , a company that saw its latest product line propel its shares 98% higher in 2013.
Hot Life Sciences Stocks To Buy Right Now: Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.
The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.
Advisors' Opinion:- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.
- [By Ben Levisohn]
Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.
BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.
Hot Life Sciences Stocks To Buy Right Now: Yahoo! Inc.(YHOO)
Yahoo! Inc., together with its subsidiaries, operates as a digital media company that delivers personalized digital content and experiences through various devices worldwide. It offers online properties and services to users; and a range of marketing services to businesses. The company?s communications and communities offerings include Yahoo! Mail, Yahoo! Messenger, Yahoo! Groups, Yahoo! Answers, Flickr, and Connected TV, which provide a range of communication and social services to users and small businesses enabling users to organize into groups and share knowledge, common interests, and photos. Its search products comprise Yahoo! Search and Yahoo! Local, available free to users to navigate the Internet and discover content. The company?s marketplaces offerings and services include Yahoo! Shopping, Yahoo! Travel, Yahoo! Real Estate, Yahoo! Autos, and Yahoo! Small Business, which allow users to research specific topics, products, services, or areas of interest by review ing and exchanging information, obtaining contact details, or considering offers from providers of goods, services, or parties with similar interests. Its media offerings comprise Yahoo! Homepage, Yahoo! News, Yahoo! Sports, Yahoo! Finance, My Yahoo!, Yahoo! Toolbar, Yahoo! Entertainment & Lifestyles, Yahoo! Contributor Network, and Yahoo! Pulse, which are designed to engage users with online content and services on the Web. The company also offers marketing services, such as display and search advertising, listing-based services, and commerce-based transactions to advertisers. In addition, it provides software and platform offerings for third-party developers, advertisers, and publishers, such as Yahoo! Developer Network, Yahoo! Open Strategy, Yahoo! Application Platform, Yahoo! Updates, Yahoo! Query Language, and Yahoo! Search BOSS. The company has strategic alliances with Nokia and ABC News, Inc. Yahoo! Inc. was founded in 1994 and is headquartered in Sunnyvale, Californi a.
Advisors' Opinion:- [By Laura Brodbeck]
Next week investors will be waiting for several key earnings reports including�General Electric Company (NYSE: GE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Peabody Energy Corporation (NYSE: BTU), Nokia Corporation (NYSE: NOK), PrivateBancorp, Inc. (NASDAQ: PVTB),Yahoo! Inc. (NASDAQ: YHOO), Bank of America Corp (NYSE: BAC) and Verizon Communications Inc. (NYSE: VZ).
- [By Rick Munarriz]
Briefly in the news
Rite Aid (NYSE: RAD ) soared after posting its first quarterly profit in six years. There were a few one-time benefits padding those results, and comps clocked in with a 2% decline, but the end result is that the drugstore chain continues to improve its operations. Alcoa (NYSE: AA ) kicked off the week by posting a surprising increase in adjusted profitability. Analysts figured that the aluminum giant would be posting a decline on the bottom line. Reports surface this week, indicating that Apple (NASDAQ: AAPL ) is in talks with Yahoo! (NASDAQ: YHOO ) to expand Yahoo!'s presence on Apple devices. Yahoo! already provides the default weather and stock quote applications for iOS gadgetry. You'll know a deal's in place when Apple adopts the exclamation point at the end of its name.
And now let's take a quick look at some of the other stories that shaped our week.
Hot Life Sciences Stocks To Buy Right Now: ICON plc(ICLR)
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies. The company?s clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, patient safety monitoring, clinical data management, interactive voice response, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, and health economics. Its clinical research services also comprise marker access and commercialization services, strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynam ic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, medical imaging, contract staffing, and electronic endpoint adjudication. In addition, the company offers various laboratory services, such as sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.
Advisors' Opinion:- [By Louis Navellier]
European Stocks to Buy: ICON Public Limited (ICLR)
ICON Public Limited Company (ICLR) is a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and Europe. They provide management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies as well as lab services for companies conducting trials. The company has posted triple digit earnings gains and posted four consecutive positive earnings surprises in the past year. Analysts have been raising their estimates for the Irish company and Portfolio Grader raised the stock to an A last month. The stock is a strong buy at today�� price.
No comments:
Post a Comment